Is it Time to Dump Harrow Inc (HROW) Stock After it Has Fallen 6.63% in a Week?

Harrow Inc (HROW) stock is down 6.63% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Harrow Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on HROW!

See Full HROW Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With HROW Stock Today?

Harrow Inc (HROW) stock has fallen -1.93% while the S&P 500 has gained 0.01% as of 12:22 PM on Thursday, Nov 9. HROW is down -$0.25 from the previous closing price of $12.93 on volume of 196,627 shares. Over the past year the S&P 500 has risen 14.50% while HROW has gained 8.75%. HROW lost -$0.56 per share in the over the last 12 months.

More About Harrow Inc

Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits. Click Here to get the full Stock Report for Harrow Inc stock.